Nkarta (NASDAQ:NKTX) Price Target Lowered to $26.00 at Mizuho

Nkarta (NASDAQ:NKTXGet Rating) had its target price reduced by Mizuho from $81.00 to $26.00 in a research note issued to investors on Wednesday morning, The Fly reports. Mizuho currently has a buy rating on the stock.

Several other equities analysts also recently weighed in on NKTX. Needham & Company LLC began coverage on shares of Nkarta in a research note on Thursday, July 28th. They issued a buy rating and a $26.00 target price for the company. Canaccord Genuity Group initiated coverage on shares of Nkarta in a research note on Monday, October 10th. They set a buy rating and a $25.00 price objective for the company. Cantor Fitzgerald reaffirmed an overweight rating on shares of Nkarta in a research note on Wednesday, September 21st. Oppenheimer reduced their price objective on shares of Nkarta from $50.00 to $36.00 and set an outperform rating for the company in a research note on Thursday, November 10th. Finally, Canaccord Genuity Group initiated coverage on shares of Nkarta in a research note on Monday, October 10th. They set a buy rating and a $25.00 price objective for the company. Ten investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Nkarta presently has a consensus rating of Buy and a consensus price target of $30.90.

Nkarta Stock Down 3.6 %

NKTX opened at $9.32 on Wednesday. The company has a market capitalization of $454.91 million, a price-to-earnings ratio of -3.49 and a beta of 0.13. The firm has a 50-day moving average price of $12.55 and a 200-day moving average price of $13.55. Nkarta has a twelve month low of $7.55 and a twelve month high of $20.35.

Insiders Place Their Bets

In other Nkarta news, CEO Paul J. Hastings sold 23,376 shares of the business’s stock in a transaction that occurred on Wednesday, September 28th. The shares were sold at an average price of $13.03, for a total value of $304,589.28. Following the completion of the transaction, the chief executive officer now owns 250,959 shares of the company’s stock, valued at approximately $3,269,995.77. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Nkarta news, CEO Paul J. Hastings sold 6,126 shares of the business’s stock in a transaction that occurred on Wednesday, September 21st. The shares were sold at an average price of $13.01, for a total value of $79,699.26. Following the completion of the transaction, the chief executive officer now owns 274,335 shares of the company’s stock, valued at approximately $3,569,098.35. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Paul J. Hastings sold 23,376 shares of the business’s stock in a transaction that occurred on Wednesday, September 28th. The stock was sold at an average price of $13.03, for a total transaction of $304,589.28. Following the completion of the sale, the chief executive officer now owns 250,959 shares of the company’s stock, valued at $3,269,995.77. The disclosure for this sale can be found here. Insiders sold a total of 30,344 shares of company stock valued at $396,093 in the last quarter. Corporate insiders own 5.60% of the company’s stock.

Institutional Investors Weigh In On Nkarta

A number of hedge funds have recently made changes to their positions in NKTX. Parkwood LLC bought a new stake in shares of Nkarta in the 2nd quarter worth approximately $31,000. Quantbot Technologies LP lifted its holdings in shares of Nkarta by 39.1% in the 1st quarter. Quantbot Technologies LP now owns 3,200 shares of the company’s stock worth $36,000 after acquiring an additional 900 shares during the last quarter. Denali Advisors LLC bought a new stake in shares of Nkarta in the 2nd quarter worth approximately $38,000. Point72 Hong Kong Ltd bought a new stake in shares of Nkarta in the 3rd quarter worth approximately $46,000. Finally, Federated Hermes Inc. lifted its holdings in shares of Nkarta by 735.3% in the 1st quarter. Federated Hermes Inc. now owns 4,711 shares of the company’s stock worth $54,000 after acquiring an additional 4,147 shares during the last quarter.

Nkarta Company Profile

(Get Rating)

Nkarta, Inc, a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.

Read More

The Fly logo

Analyst Recommendations for Nkarta (NASDAQ:NKTX)

Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.